NeuVasQ
Leuven, Belgium· Est.
Neuvasq Biotechnologies is pioneering the development of first-in-class Gpr124- and Reck-targeting Wnt surrogate antibodies, designed to restore the integrity
Private Company
Total funding raised: $3M
About
Neuvasq Biotechnologies is pioneering the development of first-in-class Gpr124- and Reck-targeting Wnt surrogate antibodies, designed to restore the integrity
BiologicsSmall Molecules
Funding History
1Total raised:$3M
Seed$3M